Encyclopedia of Molecular Pharmacology

Living Edition
| Editors: Stefan Offermanns, Walter Rosenthal

Antiarrhythmic Drugs

  • Jordi Heijman
  • Dobromir DobrevEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-030-21573-6_164-1
  • 84 Downloads

Synonyms

Definition

Antiarrhythmic drugs (AADs) are a group of pharmaceuticals used to treat or prevent heart rhythm disorders (cardiac arrhythmias) by altering the electrophysiological properties of the heart, typically through direct interaction with ion channels, receptors, or pumps/exchangers (Dan et al. 2018).

Basic Characteristics

Clinical Use

During a normal heartbeat, electrical impulses generated in the sinoatrial node conduct across the atria to the atrioventricular node. After a brief delay, the electrical impulse rapidly conducts along the His-Purkinje conduction system, resulting in synchronous activation of both ventricles that is necessary for optimal pump function of the heart. During cardiac arrhythmias, electrical impulse formation and/or conduction is disturbed, leading to excessively fast, slow, or irregular electrical activity of one or more parts of the heart. Although cardiac arrhythmias can be completely asymptomatic, they often lead...

This is a preview of subscription content, log in to check access.

References

  1. Aguilar M, Nattel S (2015) The past, present, and potential future of sodium channel block as an atrial fibrillation suppressing strategy. J Cardiovasc Pharmacol 66(5):432–440.  https://doi.org/10.1097/FJC.0000000000000271CrossRefPubMedGoogle Scholar
  2. Camm AJ (2017) Hopes and disappointments with antiarrhythmic drugs. Int J Cardiol 237:71–74.  https://doi.org/10.1016/j.ijcard.2017.03.056CrossRefPubMedGoogle Scholar
  3. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, van Gelder I, Gorenek B, Kaski JC, Kjeldsen K, Lip GYH, Merkely B, Okumura K, Piccini JP, Potpara T, Poulsen BK, Saba M, Savelieva I, Tamargo JL, Wolpert C, Group ESCSD (2018) Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace 20(5):731–732an.  https://doi.org/10.1093/europace/eux373CrossRefPubMedGoogle Scholar
  4. Grandi E, Ripplinger CM (2019) Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res 146:104274.  https://doi.org/10.1016/j.phrs.2019.104274CrossRefPubMedGoogle Scholar
  5. Heijman J, Heusch G, Dobrev D (2013) Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights Cardiol 7:127–140.  https://doi.org/10.4137/CMC.S8445CrossRefPubMedPubMedCentralGoogle Scholar
  6. Heijman J, Ghezelbash S, Dobrev D (2017) Investigational antiarrhythmic agents: promising drugs in early clinical development. Expert Opin Investig Drugs 26(8):897–907.  https://doi.org/10.1080/13543784.2017.1353601CrossRefPubMedPubMedCentralGoogle Scholar
  7. Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR (2017) The clinical use of ivabradine. J Am Coll Cardiol 70(14):1777–1784.  https://doi.org/10.1016/j.jacc.2017.08.038CrossRefPubMedGoogle Scholar
  8. Lei M, Wu L, Terrar DA, Huang CL (2018) Modernized classification of cardiac antiarrhythmic drugs. Circulation 138(17):1879–1896.  https://doi.org/10.1161/CIRCULATIONAHA.118.035455CrossRefPubMedGoogle Scholar
  9. Mankad P, Kalahasty G (2019) Antiarrhythmic drugs: risks and benefits. Med Clin North Am 103(5):821–834.  https://doi.org/10.1016/j.mcna.2019.05.004CrossRefPubMedGoogle Scholar
  10. Scalese MJ, Salvatore DJ (2017) Role of digoxin in atrial fibrillation. J Pharm Pract 30(4):434–440.  https://doi.org/10.1177/0897190016642361CrossRefPubMedGoogle Scholar
  11. Woods CE, Olgin J (2014) Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res 114(9):1532–1546.  https://doi.org/10.1161/CIRCRESAHA.114.302362CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg New York 2020

Authors and Affiliations

  1. 1.Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine, and Life SciencesMaastricht UniversityMaastrichtThe Netherlands
  2. 2.Institute of Pharmacology, West German Heart and Vascular CenterUniversity Duisburg-EssenEssenGermany